NatureCellLtd（A007390）株式概要ネイチャーセル社は韓国で缶詰、健康機能食品、飲料、幹細胞、化粧品の製造・販売を行っている。 詳細A007390 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析リスクチェックの結果、A007390 、リスクは検出されなかった。すべてのリスクチェックを見るA007390 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩22.50k1.9k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-30b32b2016201920222025202620282031Revenue ₩20.7bEarnings ₩3.8bAdvancedSet Fair ValueView all narrativesNatureCell Co.,Ltd. 競合他社QurientSymbol: KOSDAQ:A115180Market cap: ₩1.2tJS LinkSymbol: KOSDAQ:A127120Market cap: ₩1.4tGC BiopharmaSymbol: KOSE:A006280Market cap: ₩1.6tAbClonSymbol: KOSDAQ:A174900Market cap: ₩808.0b価格と性能株価の高値、安値、推移の概要NatureCellLtd過去の株価現在の株価₩22,500.0052週高値₩39,350.0052週安値₩16,550.00ベータ0.371ヶ月の変化8.96%3ヶ月変化-5.06%1年変化-5.06%3年間の変化112.46%5年間の変化60.14%IPOからの変化1,143.09%最新ニュースお知らせ • Feb 11NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea分析記事 • Oct 19We're Interested To See How NatureCellLtd (KOSDAQ:007390) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, NatureCellLtd...分析記事 • May 22Risks Still Elevated At These Prices As NatureCell Co.,Ltd. (KOSDAQ:007390) Shares Dive 27%NatureCell Co.,Ltd. ( KOSDAQ:007390 ) shares have retraced a considerable 27% in the last month, reversing a fair...分析記事 • Mar 21NatureCell Co.,Ltd.'s (KOSDAQ:007390) Share Price Not Quite Adding UpYou may think that with a price-to-sales (or "P/S") ratio of 38.5x NatureCell Co.,Ltd. ( KOSDAQ:007390 ) is a stock to...お知らせ • Feb 12NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 11:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea分析記事 • Dec 30Here's Why We're Not Too Worried About NatureCellLtd's (KOSDAQ:007390) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, NatureCellLtd...最新情報をもっと見るRecent updatesお知らせ • Feb 11NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea分析記事 • Oct 19We're Interested To See How NatureCellLtd (KOSDAQ:007390) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, NatureCellLtd...分析記事 • May 22Risks Still Elevated At These Prices As NatureCell Co.,Ltd. (KOSDAQ:007390) Shares Dive 27%NatureCell Co.,Ltd. ( KOSDAQ:007390 ) shares have retraced a considerable 27% in the last month, reversing a fair...分析記事 • Mar 21NatureCell Co.,Ltd.'s (KOSDAQ:007390) Share Price Not Quite Adding UpYou may think that with a price-to-sales (or "P/S") ratio of 38.5x NatureCell Co.,Ltd. ( KOSDAQ:007390 ) is a stock to...お知らせ • Feb 12NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 11:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea分析記事 • Dec 30Here's Why We're Not Too Worried About NatureCellLtd's (KOSDAQ:007390) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, NatureCellLtd...分析記事 • Nov 22NatureCell Co.,Ltd. (KOSDAQ:007390) Stock Rockets 88% As Investors Are Less Pessimistic Than ExpectedNatureCell Co.,Ltd. ( KOSDAQ:007390 ) shareholders have had their patience rewarded with a 88% share price jump in the...Reported Earnings • Nov 13Third quarter 2024 earnings released: ₩9.00 loss per share (vs ₩16.00 loss in 3Q 2023)Third quarter 2024 results: ₩9.00 loss per share (improved from ₩16.00 loss in 3Q 2023). Revenue: ₩5.82b (up 51% from 3Q 2023). Net loss: ₩539.1m (loss narrowed 48% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.New Risk • Jul 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩24b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change).分析記事 • Jul 16We Think NatureCellLtd (KOSDAQ:007390) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • May 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩24b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩3.00 (vs ₩41.66 loss in 1Q 2023)First quarter 2024 results: EPS: ₩3.00 (up from ₩41.66 loss in 1Q 2023). Revenue: ₩9.09b (up 60% from 1Q 2023). Net income: ₩167.1m (up ₩2.84b from 1Q 2023). Profit margin: 1.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.New Risk • Mar 30New major risk - Revenue and earnings growthRevenue has declined by 8.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 8.9% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).分析記事 • Mar 22We Think NatureCellLtd (KOSDAQ:007390) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Buying Opportunity • Jan 08Now 22% undervaluedOver the last 90 days, the stock is up 2.2%. The fair value is estimated to be ₩10,069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last year. Earnings per share has grown by 81%.Buying Opportunity • Nov 28Now 20% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be ₩10,069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last year. Earnings per share has grown by 81%.New Risk • Jul 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).お知らせ • Jun 30NatureCell Co.,Ltd. announced that it has received KRW 5 billion in fundingOn June 29, 2023, NatureCell Co.,Ltd. closed the transaction. The scheduled listing of the share is July 14, 2023 and all new stock is locked up for one year from closing date.お知らせ • Jun 14NatureCell Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingNatureCell Co.,Ltd. announced a private placement of 500,000 common shares at a price of KRW 10,000 per share for the gross proceeds of KRW 5,000,000,000 on June 13, 2023. The transaction will include participation from returning investor Jeongchan Ra for 500,000 shares. The shares are restricte to hold period of 1 year. The transaction has been approved by the shareholders of the company. The transaction is expected to close on July 14, 2023.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 14NatureCell Co.,Ltd. announced that it expects to receive KRW 30 billion in fundingNatureCell Co.,Ltd. announced a private placement series 4 bearer type private equity convertible bonds with bearer interest for gross proceeds KRW 30,000,000,000 in a round of funding on April 12, 2022. The transaction will include participation from Green Snake Bio Technology Association No. 1. The bonds will carry a fixed surface interest rate of 1% and maturity rate of 2%. The bonds have a maturity date of May 20, 2025. The bonds are 100% convertible at a fixed conversion price of KRW 17,652 into 1,699,514 common shares from May 20, 2023 to April 20, 2025. The subscription date of the bonds is April 12, 2022. The company expects to close the transaction on May 20, 2022. The transaction was approved by the board of directors of the company. The securities carry a lock up period of one year.Is New 90 Day High Low • Feb 24New 90-day low: ₩7,840The company is down 18% from its price of ₩9,510 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 12% over the same period.お知らせ • Feb 10NatureCell Co.,Ltd., Annual General Meeting, Mar 30, 2021NatureCell Co.,Ltd., Annual General Meeting, Mar 30, 2021, at 11:00 Korea Standard Time.Is New 90 Day High Low • Jan 29New 90-day low: ₩8,900The company is down 2.0% from its price of ₩9,120 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 16% over the same period.Is New 90 Day High Low • Dec 30New 90-day high: ₩10,250The company is up 4.0% from its price of ₩9,850 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Food industry, which is up 1.0% over the same period.Is New 90 Day High Low • Nov 17New 90-day low: ₩9,110The company is down 12% from its price of ₩10,350 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is down 8.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: ₩9,120The company is down 4.0% from its price of ₩9,480 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Food industry, which is down 8.0% over the same period.お知らせ • Sep 01NatureCell Co.,Ltd. announced that it has received KRW 10 billion in fundingOn August 26, 2020, NatureCell Co.,Ltd. (KOSDAQ:A007390) closed the transaction.お知らせ • Aug 25NatureCell Co.,Ltd. announced that it expects to receive KRW 10 billion in fundingNatureCell Co.,Ltd. (KOSDAQ:A007390) announced that it will receive KRW 10,000,000,000 in a round of funding on August 24, 2020. The company will issue series 3 non-guaranteed private equity convertible bonds with bearer interest in the transaction. The transaction will include participation from Las Bora Fund. The bonds will carry a fixed surface interest rate of 1% and interest to maturity of 1%. The bonds have a maturity date of August 26, 2023. The bonds are 100% convertible at a fixed conversion price of KRW 10,539 into 948,845 common shares from August 26, 2021 to July 26, 2023. The subscription date of the bonds is August 24, 2020. The transaction was approved by the board of directors of the company. The company expects to close the transaction on August 26, 2020.株主還元A007390KR BiotechsKR 市場7D25.0%0.3%4.6%1Y-5.1%33.1%186.7%株主還元を見る業界別リターン: A007390過去 1 年間で33.1 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A007390は、過去 1 年間で186.7 % のリターンを上げたKR市場を下回りました。価格変動Is A007390's price volatile compared to industry and market?A007390 volatilityA007390 Average Weekly Movement12.5%Biotechs Industry Average Movement11.5%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%安定した株価: A007390 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A007390の 週次ボラティリティ ( 13% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト196077n/awww.naturecell.co.kr株式会社ネイチャーセルは韓国で缶詰、健康機能性食品、飲料、幹細胞、化粧品の製造・販売を行っている。同社の製品はフルーツドリンク、アロエベラドリンク、コーヒー、エナジードリンク、韓国風ソースで構成され、SAMMIおよびOEMブランドで国内製品およびその他のETC製品を提供している。また、内皮前駆細胞、単核細胞、血小板豊富血漿製品などの保存用血液細胞サービスも提供している。同社は以前はRNL Sammi CO,Ltd.として知られていたが、2013年4月に社名をNatureCell Co,Ltd.に変更した。ネイチャーセル社は1960年に設立され、韓国ソウルに本社を置いている。もっと見るNatureCell Co.,Ltd. 基礎のまとめNatureCellLtd の収益と売上を時価総額と比較するとどうか。A007390 基礎統計学時価総額₩1.45t収益（TTM）-₩2.84b売上高(TTM)₩20.73b69.9xP/Sレシオ-510.8xPER（株価収益率A007390 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A007390 損益計算書（TTM）収益₩20.73b売上原価₩11.28b売上総利益₩9.45bその他の費用₩12.29b収益-₩2.84b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-44.05グロス・マージン45.60%純利益率-13.69%有利子負債／自己資本比率7.9%A007390 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 11:06終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NatureCell Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 11NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea
分析記事 • Oct 19We're Interested To See How NatureCellLtd (KOSDAQ:007390) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, NatureCellLtd...
分析記事 • May 22Risks Still Elevated At These Prices As NatureCell Co.,Ltd. (KOSDAQ:007390) Shares Dive 27%NatureCell Co.,Ltd. ( KOSDAQ:007390 ) shares have retraced a considerable 27% in the last month, reversing a fair...
分析記事 • Mar 21NatureCell Co.,Ltd.'s (KOSDAQ:007390) Share Price Not Quite Adding UpYou may think that with a price-to-sales (or "P/S") ratio of 38.5x NatureCell Co.,Ltd. ( KOSDAQ:007390 ) is a stock to...
お知らせ • Feb 12NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 11:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea
分析記事 • Dec 30Here's Why We're Not Too Worried About NatureCellLtd's (KOSDAQ:007390) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, NatureCellLtd...
お知らせ • Feb 11NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea
分析記事 • Oct 19We're Interested To See How NatureCellLtd (KOSDAQ:007390) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, NatureCellLtd...
分析記事 • May 22Risks Still Elevated At These Prices As NatureCell Co.,Ltd. (KOSDAQ:007390) Shares Dive 27%NatureCell Co.,Ltd. ( KOSDAQ:007390 ) shares have retraced a considerable 27% in the last month, reversing a fair...
分析記事 • Mar 21NatureCell Co.,Ltd.'s (KOSDAQ:007390) Share Price Not Quite Adding UpYou may think that with a price-to-sales (or "P/S") ratio of 38.5x NatureCell Co.,Ltd. ( KOSDAQ:007390 ) is a stock to...
お知らせ • Feb 12NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 11:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea
分析記事 • Dec 30Here's Why We're Not Too Worried About NatureCellLtd's (KOSDAQ:007390) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, NatureCellLtd...
分析記事 • Nov 22NatureCell Co.,Ltd. (KOSDAQ:007390) Stock Rockets 88% As Investors Are Less Pessimistic Than ExpectedNatureCell Co.,Ltd. ( KOSDAQ:007390 ) shareholders have had their patience rewarded with a 88% share price jump in the...
Reported Earnings • Nov 13Third quarter 2024 earnings released: ₩9.00 loss per share (vs ₩16.00 loss in 3Q 2023)Third quarter 2024 results: ₩9.00 loss per share (improved from ₩16.00 loss in 3Q 2023). Revenue: ₩5.82b (up 51% from 3Q 2023). Net loss: ₩539.1m (loss narrowed 48% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩24b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change).
分析記事 • Jul 16We Think NatureCellLtd (KOSDAQ:007390) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • May 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩24b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩3.00 (vs ₩41.66 loss in 1Q 2023)First quarter 2024 results: EPS: ₩3.00 (up from ₩41.66 loss in 1Q 2023). Revenue: ₩9.09b (up 60% from 1Q 2023). Net income: ₩167.1m (up ₩2.84b from 1Q 2023). Profit margin: 1.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
New Risk • Mar 30New major risk - Revenue and earnings growthRevenue has declined by 8.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 8.9% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
分析記事 • Mar 22We Think NatureCellLtd (KOSDAQ:007390) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Buying Opportunity • Jan 08Now 22% undervaluedOver the last 90 days, the stock is up 2.2%. The fair value is estimated to be ₩10,069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last year. Earnings per share has grown by 81%.
Buying Opportunity • Nov 28Now 20% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be ₩10,069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last year. Earnings per share has grown by 81%.
New Risk • Jul 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
お知らせ • Jun 30NatureCell Co.,Ltd. announced that it has received KRW 5 billion in fundingOn June 29, 2023, NatureCell Co.,Ltd. closed the transaction. The scheduled listing of the share is July 14, 2023 and all new stock is locked up for one year from closing date.
お知らせ • Jun 14NatureCell Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingNatureCell Co.,Ltd. announced a private placement of 500,000 common shares at a price of KRW 10,000 per share for the gross proceeds of KRW 5,000,000,000 on June 13, 2023. The transaction will include participation from returning investor Jeongchan Ra for 500,000 shares. The shares are restricte to hold period of 1 year. The transaction has been approved by the shareholders of the company. The transaction is expected to close on July 14, 2023.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 14NatureCell Co.,Ltd. announced that it expects to receive KRW 30 billion in fundingNatureCell Co.,Ltd. announced a private placement series 4 bearer type private equity convertible bonds with bearer interest for gross proceeds KRW 30,000,000,000 in a round of funding on April 12, 2022. The transaction will include participation from Green Snake Bio Technology Association No. 1. The bonds will carry a fixed surface interest rate of 1% and maturity rate of 2%. The bonds have a maturity date of May 20, 2025. The bonds are 100% convertible at a fixed conversion price of KRW 17,652 into 1,699,514 common shares from May 20, 2023 to April 20, 2025. The subscription date of the bonds is April 12, 2022. The company expects to close the transaction on May 20, 2022. The transaction was approved by the board of directors of the company. The securities carry a lock up period of one year.
Is New 90 Day High Low • Feb 24New 90-day low: ₩7,840The company is down 18% from its price of ₩9,510 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 12% over the same period.
お知らせ • Feb 10NatureCell Co.,Ltd., Annual General Meeting, Mar 30, 2021NatureCell Co.,Ltd., Annual General Meeting, Mar 30, 2021, at 11:00 Korea Standard Time.
Is New 90 Day High Low • Jan 29New 90-day low: ₩8,900The company is down 2.0% from its price of ₩9,120 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 16% over the same period.
Is New 90 Day High Low • Dec 30New 90-day high: ₩10,250The company is up 4.0% from its price of ₩9,850 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Food industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Nov 17New 90-day low: ₩9,110The company is down 12% from its price of ₩10,350 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: ₩9,120The company is down 4.0% from its price of ₩9,480 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Food industry, which is down 8.0% over the same period.
お知らせ • Sep 01NatureCell Co.,Ltd. announced that it has received KRW 10 billion in fundingOn August 26, 2020, NatureCell Co.,Ltd. (KOSDAQ:A007390) closed the transaction.
お知らせ • Aug 25NatureCell Co.,Ltd. announced that it expects to receive KRW 10 billion in fundingNatureCell Co.,Ltd. (KOSDAQ:A007390) announced that it will receive KRW 10,000,000,000 in a round of funding on August 24, 2020. The company will issue series 3 non-guaranteed private equity convertible bonds with bearer interest in the transaction. The transaction will include participation from Las Bora Fund. The bonds will carry a fixed surface interest rate of 1% and interest to maturity of 1%. The bonds have a maturity date of August 26, 2023. The bonds are 100% convertible at a fixed conversion price of KRW 10,539 into 948,845 common shares from August 26, 2021 to July 26, 2023. The subscription date of the bonds is August 24, 2020. The transaction was approved by the board of directors of the company. The company expects to close the transaction on August 26, 2020.
